AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimer’s and Parkinson’s Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain Delivery

AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimer’s and Parkinson’s Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain Delivery

Neurodegenerative disorders are a major public health issue. Despite decades of research efforts, we are still seeking an efficient cure for these pathologies. The initial paradigm of large aggregates of amyloid proteins (amyloid plaques, Lewis bodies) as the root cause of Alzheimer’s and Parkinson’...

Full description

Bibliographic Details
Main Authors: Coralie Di Scala, Nicholas Armstrong, Henri Chahinian, Eric Chabrière, Jacques Fantini, Nouara Yahi
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:International Journal of Molecular Sciences
Subjects:
Alzheimer’s
Parkinson’s
therapy
peptide
ganglioside
amyloid pore
Online Access:https://www.mdpi.com/1422-0067/23/21/13383

Internet

https://www.mdpi.com/1422-0067/23/21/13383

Similar Items